- Back |
- Home
- / News
- / Product News
- / The first domestic hematological tumor MRD detection product was approved by CE, and Shenzhen Neoimmune Co., Ltd has built a benchmark enterprise for clinical immunodetection
The first domestic hematological tumor MRD detection product was approved by CE, and Shenzhen Neoimmune Co., Ltd has built a benchmark enterprise for clinical immunodetection
MRD (Minimal Residual Disease) refers to the state of trace tumor cells left in the body after treatment for malignant tumors, which is the root cause of tumor recurrence. Accurate MRD testing is the foundation for personalized precision medicine for patients, predicting clinical outcomes and stratifying the patient's level of risk, guiding treatment decisions, predicting tumor recurrence early, and determining the optimal time for bone marrow or stem cell transplantation.
In recent years, the MRD testing market at home and abroad has gradually heated up and developed by leaps and bounds. In 2018, the FDA approved clonoSEQ® for MRD detection and surveillance in multiple myeloma and B-cell acute lymphoblastic leukemia (ALL); In 2020, the FDA approved clonoSEQ® for MRD testing in lymphocytic leukemia (CLL) blood or bone marrow samples. In China, many companies, including Pan-Cause Medicine, are also focusing on MRD detection product research.
Recently, China's MRD testing market has ushered in a major breakthrough. In March 2021, NEO-MRD, the first domestic hematological tumor MRD detection product developed by Shenzhen Neoimmune Co., Ltd, obtained the EU CE access qualification. Based on the NGS platform, NEO-MRD has the characteristics of high detection rate, high accuracy and automation, and can also monitor the emergence of new high-frequency clones and evaluate the reconstruction of the immune system, which can greatly contribute to the development of the global hematological tumor microresidual disease industry.
Current commonly used MRD detection techniques include fusion gene RT-PCR, flow cytometry, IgH/TCR rearrangement quantitative PCR and NGS. Flow cytometry and PCR technology have been widely used in clinical practice, but there are still pain points such as insufficient sensitivity to accurately predict prognosis, insufficient standardization of operations, inability to monitor new tumor clones, and inability to evaluate immune system reconstruction.
As an emerging MRD detection method, NGS can significantly reduce the recurrence rate of patients and improve the survival time of patients, and has been recognized and recommended by experts at home and abroad. The Standards for the Diagnosis and Treatment of Acute Lymphoblastic Leukemia in Children (2018 Edition), the Standards for the Diagnosis and Treatment of Adult Acute Lymphoblastic Leukemia (2018 Edition), and the Chinese Guidelines for the Diagnosis and Treatment of Multiple Myeloma (revised in 2020) all recommend NGS as a detection method for MRD.
NGS detection method compared with traditional commonly used detection methods
According to Liu Xiao, founder of Shenzhen Neoimmune Co., Ltd, NEO-MRD, a hematological tumor MRD detection product based on the NGS platform developed by Pan-Cause Medicine, effectively makes up for the shortcomings of traditional technologies such as flow cytometry and PCR technology, and has multiple advantages such as high accuracy, high sensitivity and high detection rate.
Accurate and sensitive experimental system. Based on accurate and unbiased multiplex amplification technology and leading bioinformatics algorithms, NEO-MRD targets multiple rearrangement sites, has high sensitivity and accuracy, and is not affected by tumor cell surface antigen drift and clonal evolution.
Easy operation, standardization and automation of processes. NEO-MRD is fully automated from DNA to test report, which can reduce human operation errors and improve repeatability.
The detection rate is high, and the detection rate of tumor cells is improved by amplifying the receptor chain. The NEO-MRD experimental system includes receptor chains of IGH, IGK, IGL, TRB, TRG, which can accurately identify the marker sequence of tumor cells, and each chain also includes primers in different positions (FR1, FR2, FR3), which can effectively avoid false negatives or inaccurate quantification caused by mutations of tumor cells. Among the 58 real clinical samples, the consistency of the two methods was good for 25 samples with positive NGS and flow cytometry, 14 samples were negative for flow cytometry, positive for NGS, and 19 samples were negative for both.
NEO-MRD can monitor the emergence of new high-frequency clones and assess the risk of recurrence due to subcloning or evolutionary cloning of the original tumor subclone. At the same time, NEO-MRD can also evaluate the reconstitution of the immune system.
Original bioinformatics analysis tool. Due to the extremely low MRD levels of some samples, sequencing errors and sequence contamination need to be tightly controlled. Through original data processing technology, Pan-Cause Medicine can effectively correct sequencing errors and remove trace contamination that may occur during the experimental process to ensure the accuracy of detection.
At present, Pan-Cause Medicine is carrying out scientific research and academic cooperation with a large number of clinicians to improve the detection rate of MRD in hematological tumors and jointly promote the clinical application of MRD detection products for hematological tumors.
At present, the overall market of immunodetection in China is in a stage of rapid development, mainly based on chemiluminescence, biochemical detection, flow cytometry and other technical platforms, chemiluminescence, biochemical detection and other fields of fierce competition, crowded tracks. But in fact, clinical immunological testing is not saturated, there are a large number of unmet needs, and new technologies with high sensitivity and high portability have a huge market space.
Liu Xiao said: "Due to the insufficient understanding of the immune system, there are not many clinically available targets, and the diagnosis, molecular typing and prognosis monitoring of many immune-related diseases require more sensitive and clinically valuable detection targets. In addition, clinical immunoassays also have shortcomings such as insufficient sensitivity, portability, and clinical interpretability, and NGS, digital PCR, next-generation flow cytometry and other technologies are urgently needed to expand the detection horizon of traditional methods. ”
The core team of Shenzhen Neoimmune Co., Ltd has more than ten years of technology development and scientific research experience in the field of high-throughput immunomics, and has in-depth understanding and rich experience in basic and medical immunology, genomics, bioinformatics and clinical needs. Chairman Dr. Liu Xiao is an expert of the Ministry of Science and Technology of the People's Republic of China, an associate professor and doctoral supervisor of Tsinghua University, and has published more than 70 SCI papers, and his team is the earliest scientific research team in China to study IR-seq technology.
"NGS technology, as a high-sensitivity and high-throughput molecular detection platform, has broad application prospects, and we believe that the immunodetection market is the next flashpoint of NGS technology." Thus, pan-causal medicine was founded. "We hope to make use of the years of accumulation of the pan-cause medical team in the field of technology and science, establish a high-throughput technology platform for digital interpretation, functional verification and editing and transformation of immune cells, rely on big data mining, achieve rapid iteration of target discovery, clinical validation and product development, develop immunodetection products with the characteristics of multi-target, high-throughput, high sensitivity, and standardization, and quickly promote the clinical application transformation of immunoomics."
In less than a year since its establishment, Shenzhen Neoimmune Co., Ltd has reached partnerships with many top hospitals in China, successfully built a FAIR-seq platform, a big data analysis platform and a large-scale clinical immunological group database.
In terms of product layout, in addition to hematological tumor MRD detection products, Shenzhen Neoimmune Co., Ltd is also developing other tumor and infectious disease related products, including tumor immunotherapy detection products, tumor early diagnosis and prognosis products, tumor T cell therapy products, etc., to benefit more patients with tumors and infections.
8/F, Block A, Hengtemei Building, No. 3 Ganli Road, Longgang District, Shenzhen; 402, Kelente R&D Building, Ganli Road, Longgang District, Shenzhen.